Sign up online today & collaborate
or click here to find out more
Under the terms, Celgene will pay $232 a share for Receptos, a 12% premium to Tuesday’s closing price. Receptos stock, which traded at $107.22 a share in late January, had risen in recent months amid takeover speculation.
Celgene, which expects the deal to close in the third quarter, has been trying to diversify beyond its foothold in drugs treating multiple myeloma. About 65% of its $7.6 billion in 2014 total product sales came from just one of these drugs, Revlimid. But such blood-cancer drugs are aging and rivals are challenging patents.
For more click here
Source: Wall Street Journal